On Tuesday, Chemours Co (NYSE:CC)’s shares declined -8.74% to $10.02.
The Chemours Company (CC), a global chemical company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, declared financial results for the second quarter 2015. Chemours was a wholly-owned partner of DuPont during the period, and these results reflect a stand-alone basis of presentation.
Second quarter net sales were $1.5 billion, a decrease of 10 percent from $1.7 billion in the preceding-year quarter. Second quarter net loss was $18 million, or a pro forma net loss of $0.10 per diluted share, as compared to net income of $116 million in the second quarter 2014. Adjusted EBITDA was $127 million as compared to $235 million in the preceding year quarter. Profitability was reduced as a result of 11 percent lower-global- average local TiO2 prices, about $48 million from unfavorable currency movements and about $15 million from planned and unplanned plant outages. Lower year-over-year corporate and other operating costs partially offset these impacts.
The Chemours Company, a chemical company, provides titanium technologies, fluoroproducts, and chemical solutions. Its flagship products comprise brands, such as Teflon, Ti-Pure, Krytox Viton, Opteon, and Nafion. The company produces titanium dioxide, with Ti-Pure for coatings, plastics, laminates, and paper; and fluoroproducts, counting Teflon fluoropolymers, Krytox performance lubricants, Viton fluoroelastomers, and Opteon refrigerants.
ONEOK, Inc. (NYSE:OKE)’s shares dropped -2.65% to $35.62.
ONEOK, Inc. (OKE) declared that it has priced an offering to sell $500 million of 7.50 percent senior notes due 2023. The notes will be issued under ONEOK’s existing shelf registration statement formerly filed with the U.S. Securities and Exchange Commission.
The net proceeds, after deducting underwriting discounts and estimated expenses, are predictable to be about $487.1 million. ONEOK anticipates to use the proceeds and cash on hand to purchase additional common units from ONEOK Partners, L.P. (OKS) in a private placement. Funds managed by Kayne Anderson Capital Advisors, L.P. also will purchase $100 million of common units from ONEOK Partners co presently with ONEOK’s purchase.
ONEOK is the parent company of ONEOK Partners GP, L.L.C. (General Partner), the sole general partner of ONEOK Partners. Following the common unit purchases, ONEOK’s and the General Partner’s aggregate ownership interest in ONEOK Partners will enhance to 41.2 percent from 36.8 percent.
The sole book-running manager for the offering is Citigroup. ONEOK anticipates the notes offering to close on Aug. 21, 2015.
ONEOK, Inc., through its general partner interests in ONEOK Partners, L.P., engages in the gathering, processing, storage, and transportation of natural gas in the United States. The company gathers, treats, fractionates, stores, and transports natural gas liquids (NGL), in addition to owns natural gas liquids gathering and distribution pipelines, natural gas liquids distribution and refined petroleum products pipelines, and terminal and storage facilities; and owns and operates interstate and intrastate regulated natural gas transmission pipelines and natural gas storage facilities, in addition to stores and distributes NGL products to petrochemical manufacturers, heating fuel users, ethanol producers, refineries, and propane distributors.
At the end of Tuesday’s trade, Evoke Pharma Inc (NASDAQ:EVOK)‘s shares surged 10.37% to $5.11.
Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, declared its financial results for the second quarter ended June 30, 2015.
Dave Gonyer, R.Ph., President and CEO, stated, “Entering the second half of the year, we continue to recruit subjects for our 200 patient Phase 3 clinical trial. Our trial sites continue to receive a high level of patient interest and we remain confident in our ability to complete enrollment in a timely manner. However, due to a lower percentage of subjects successfully meeting screening qualifications during July and the current 130 total enrolled subjects, we are now projecting to complete trial enrollment during the first half of 2016.
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It develops EVK-001, a metoclopramide nasal spray, which is in Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.
TD Ameritrade Holding Corp. (NYSE:AMTD), ended its Tuesday’s trading session with -1.38% loss, and closed at $35.72.
Although Americans surveyed say providing monetary support to a family member is not a financial struggle, many also maintain high debt levels and have delayed major life milestones to provide this financial assistance. TD Ameritrade’s 2015 Financial Support survey explores the struggle Americans feel towards assisting a family member in need while still in debt themselves, and reveals key differences between Generation X and Baby Boomers.1
The Real Cost of Financial Support
- One in five Americans (22 percent) provide financial support to a parent and/or an adult child (“Financial Supporters”).
- Over the past year, Financial Supporters have given $12,000 of support on average – that’s an estimated $630 billion from the US economy.2
- Few report that providing this support is causing them great financial hardship: only 22 percent say they needed to use their savings to provide financial assist while 30 percent made small sacrifices and lived more frugally.
- However, Financial Supporters hold almost $100,000 in debt on average: $22,000 in unpaid credit card balances, personal lines of credit, or personal or student loans, and $75,000 in mortgage debt.
TD Ameritrade Holding Corporation provides securities brokerage services and related technology-based financial services to retail investors, traders, and independent registered investment advisors (RIAs) in the United States. Its products and services comprise tdameritrade.com, a Web platform for self-directed retail investors; Trade Architect, a Web-based platform that enables active investors and traders identify opportunities and stay informed; thinkorswim, a desktop platform for trading; and TD Ameritrade Mobile, which allows on-the-go investors and traders to trade and monitor accounts from Web-enabled mobile devices.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
